# Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

> **NCT05186805** · PHASE2 · COMPLETED · sponsor: **Organon and Co** · enrollment: 36 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tapinarof cream, 1%

## Key facts

- **NCT ID:** NCT05186805
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-15
- **Primary completion:** 2022-08-24
- **Final completion:** 2022-08-24
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05186805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05186805, "Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05186805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*